IBS Capital sells IQuum stake to Roche
IBS Capital has sold its equity investment in IQuum to Roche.
IBS made its initial capital investment in IQuum in 1999 shortly after the firm was founded and has remained its largest outside investor over the past 15 years.
David Taft, the president of IBS, also served as a director on IQuum's board of directors since 1999. During this period, IQuum developed groundbreaking technology in molecular diagnostics.
Taft says: "IQuum's Laboratory-in-a-tube (Liat) System will dramatically improve the point of care segment of the diagnostics market and will bring significant benefits to Roche. In combination with Roche's extensive technological, marketing and financial resources, the Liat system will provide healthcare clinics and hospitals with fast, accurate and simple to use testing for a wide range of medical conditions."
- By Category
- News from other sites
- Special Reports
- Partner events